Drug Development Business Case
This is a practical guide to building a business case for a drug development project — the justification that weighs the costs, benefits and risks of doing the project, adapted to the realities of developing a pharmaceutical product through regulatory stages.
What a Business Case is
A business case is the justification that weighs the costs, benefits and risks of doing the project. For the full concept and how it works in general, see Business Case. On a drug development project it plays the same role, tuned to this kind of work.
Why it matters for a Drug Development project
Drug Development projects live or die on developing a pharmaceutical product through regulatory stages. A well-built business case gives the team a shared, explicit reference for exactly that — reducing ambiguity, aligning stakeholders, and making problems visible early enough to act. Skipping it, or doing it generically, is how drug development projects drift into avoidable delay and cost.
What to include
- Problem or opportunity
- Options considered
- Costs and benefits
- Financial appraisal (ROI/NPV/IRR)
- Recommendation
Drug Development-specific considerations
Tailor the business case to the risks that most often derail drug development projects:
- Regulatory approval delays
- Trial/validation failures
- Strict GxP compliance
Example
On a real drug development project, the business case would be shaped by developing a pharmaceutical product through regulatory stages. In particular, it should explicitly account for the project’s biggest risks — regulatory approval delays, trial/validation failures, strict GxP compliance — rather than treating them as afterthoughts.